Tango Therapeutics, Inc. (NASDAQ:TNGX) Insider Mva Investors, Llc Sells 75,000 Shares of Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) insider Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $7.43, for a total value of $557,250.00. Following the completion of the sale, the insider now owns 618,524 shares of the company’s stock, valued at $4,595,633.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Mva Investors, Llc also recently made the following trade(s):

• On Friday, May 3rd, Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock. The stock was sold at an average price of $7.61, for a total value of $456,600.00.

Tango Therapeutics Stock Performance

TNGX stock opened at $7.61 on Friday. The business has a 50-day simple moving average of $8.58 and a two-hundred day simple moving average of $9.31. The company has a market capitalization of $812.29 million, a P/E ratio of -6.92 and a beta of 0.84. Tango Therapeutics, Inc. has a 52-week low of $2.47 and a 52-week high of $13.03.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.04). Tango Therapeutics had a negative net margin of 278.55% and a negative return on equity of 41.96%. The company had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. As a group, sell-side analysts forecast that Tango Therapeutics, Inc. will post -1.28 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts recently issued reports on TNGX shares. HC Wainwright increased their target price on shares of Tango Therapeutics from $16.00 to $17.00 and gave the stock a “buy” rating in a research note on Wednesday, March 20th. Piper Sandler began coverage on shares of Tango Therapeutics in a research report on Monday, February 12th. They set an “overweight” rating and a $18.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $18.00 target price on shares of Tango Therapeutics in a research report on Monday, March 18th. Finally, Cantor Fitzgerald initiated coverage on Tango Therapeutics in a research note on Thursday, April 4th. They set an “overweight” rating on the stock. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $17.25.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. RTW Investments LP bought a new position in shares of Tango Therapeutics during the 4th quarter worth approximately $19,471,000. FMR LLC boosted its position in Tango Therapeutics by 12.3% in the third quarter. FMR LLC now owns 11,645,741 shares of the company’s stock worth $131,131,000 after purchasing an additional 1,276,945 shares during the last quarter. Boxer Capital LLC grew its stake in Tango Therapeutics by 15.1% in the 4th quarter. Boxer Capital LLC now owns 8,198,642 shares of the company’s stock valued at $81,167,000 after purchasing an additional 1,075,000 shares during the period. Deerfield Management Company L.P. Series C bought a new position in Tango Therapeutics in the 3rd quarter valued at $8,937,000. Finally, Invesco Ltd. increased its position in shares of Tango Therapeutics by 3,247.3% during the 3rd quarter. Invesco Ltd. now owns 774,738 shares of the company’s stock valued at $8,724,000 after purchasing an additional 751,593 shares during the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.